Genetic Testing for Mental Health Medications: What It Can Tell You
A clear guide to what pharmacogenomic tests can reveal, what current research suggests, and how to discuss results with your prescriber.

In this article
Finding a mental-health medication that fits can take patience. Pharmacogenomic testing offers another source of information: it looks at selected genetic differences that may affect how the body processes some medicines. For some people, that information can make a treatment conversation more specific. It is one tool—not a crystal ball—and it works best alongside your history, preferences, symptoms, and a clinician’s judgment.
What does pharmacogenomic testing look at?
Most tests used in this area are pharmacogenomic: they examine selected DNA variants that can influence how enzymes—often CYP2D6, CYP2C19, or CYP2B6—process certain medications. For some gene–medicine pairs, that information may help a prescriber consider dose or medication options. Clinical guidelines explain how to interpret some already-available results; they do not turn a test into a complete treatment plan.¹
The result does not measure how severe depression or anxiety is, reveal every cause of symptoms, or tell with certainty which medication will work best. Genes are one piece of a much larger picture, alongside prior treatment response, other medicines, health conditions, preferences, and careful follow-up.²
What can the results—and color charts—actually tell you?
Many commercial reports sort medications into color-coded groups. Those colors are a summary of the company’s interpretation of selected gene–drug information, not a pass/fail label for a medicine. A caution category does not automatically mean a drug cannot help, and a reassuring category is not a promise that it will. The FDA notes that listed gene–drug associations do not, by themselves, mean the agency recommends testing before prescribing; the strength and meaning of evidence vary by pairing.²
The most useful conversation is specific: Which gene and medication interaction is relevant? Is the result tied to an established dosing guideline or to a less-validated prediction of response? How does it fit with what you have already tried and how you felt? A prescriber or pharmacist can help translate the report into a practical question rather than a verdict.¹²
What does the clinical research show?
The encouraging possibility is that genetic information may help some clinicians avoid a medication–metabolism mismatch and make treatment choices more informed. In the 2022 PRIME Care randomized trial of 1,944 adults with major depression, giving clinicians a commercial test result reduced prescribing of antidepressants with predicted gene–drug interactions. Remission differences were modest over the study and were not statistically significant at week 24.³
A 2026 randomized trial tested genotype-guided SSRI prescribing using public clinical guidelines. Among participants with an actionable metabolism profile, symptom scores and side-effect burden did not differ at three months; remission was higher in the guided group at six months (48.3% versus 39.4% on one measure). This is a hopeful signal, while the authors note that the longer-term effect needs more study.⁴
Taken together, the findings support a measured view: testing can inform prescribing and may help some people, but benefits are not guaranteed and may depend on the specific gene, medication, test, and clinical situation. Research continues to clarify where it adds the most value.³⁴
Who might want to ask about testing?
It may be reasonable to discuss pharmacogenomic testing if you have had troublesome side effects, an unexpected response, or several medication trials that did not help enough—and if the result could inform a real decision. It may also be relevant when a prescriber is considering a medicine whose dosing guidance uses a particular gene result. Whether testing makes sense depends on your history and the treatment question, not simply on having a diagnosis.¹⁴
You do not need to exhaust every treatment option before asking. You can bring the question to your prescriber or pharmacist and decide together whether a test is likely to add useful information. Testing should not delay support or a treatment plan that already makes sense for you.
Questions to ask before ordering a test
Ask which genes and medication pairs the test evaluates, what clinical guidelines support the recommendations, who will interpret the report, and what the total out-of-pocket cost may be. You can also ask how the sample and genetic data are stored, who can access them, and whether they are used for other purposes. In the United States, federal genetic-discrimination protections have limits, including for some types of insurance.⁵⁶
Be cautious of marketing that promises to identify the one right medication or guarantee that a drug will work. The FDA has raised concerns about unapproved claims that genetic tests can predict response to specific medicines. Do not start, stop, or change a medication based on a report without discussing it with your prescriber.⁵
A tool for the conversation—not the whole answer
Mental-health treatment can involve uncertainty, but you are not limited to guessing alone. Pharmacogenomic testing may add a useful clue for some medication decisions, especially when a result connects to a well-supported gene–drug guideline. Its best role is as one part of a collaborative plan—alongside your lived experience, careful monitoring, and the many other treatment options available.
Sources
- Bousman CA, et al. CPIC Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology & Therapeutics. 2023.
- U.S. Food and Drug Administration. Table of Pharmacogenetic Associations.
- Oslin DW, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022.
- Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial. JAMA Network Open. 2026.
- U.S. Food and Drug Administration. Direct-to-Consumer Tests: Pharmacogenetics Tests.
- National Human Genome Research Institute. Genetic Information Nondiscrimination Act (GINA).
